Cisplatin Derivatives and Their Complexes with PAMAM Dendrimers—A Way to Improve the Efficacy of Anticancer Drugs
ChemMedChem · 2026
DOI: 10.1002/cmdc.202500881 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Monika Marcinkowska und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska Street., 90-236, Lodz, Poland. Hauptthemen laut MEDLINE: Dendrimers, Cisplatin, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: EU Regional Operational Program of the Lodz Region.
Abstract (Originalsprache)
Female cancers, primarily breast, cervical, and ovarian cancers, remain a major public health challenge, with rising incidence and high mortality. Cisplatin has long been a cornerstone of anticancer therapy, yet its clinical use is limited by low selectivity, severe side effects, drug resistance, and relapse. Thus, more effective and selective therapeutic strategies are needed. In this study, we evaluated the cytotoxicity and mechanisms of action of three cisplatin derivatives (C‐cisplatin, D‐cisplatin, and Ac‐cisplatin) and their complexes with generation 2 polyamidoamine (PAMAM G2) dendrimers. All drug–dendrimer complexes were prepared at a 10:1 molar ratio and tested on two cancer cell lines—HeLa (cervical cancer) and MCF‐7 (breast cancer)—and one non‐cancer human microvascular endothelial cell line (HMEC‐1). Complex formation was confirmed by zeta potential measurements. Cytotoxicity was assessed for both free and complexed drugs. To explore potential mechanisms of action, mitochondrial membrane potential and reactive oxygen species (ROS) levels were evaluated. Flow cytometry was then used to determine dominant cell‐death pathways. The complexes demonstrated cytotoxicity comparable to or greater than cisplatin and showed improved selectivity toward cancer cells. Among them, D‐cisplatin complexed with PAMAM G2 was the most promising candidate, exhibiting the highest selectivity toward HeLa cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska Street., 90-236, Lodz, Poland.
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Avenue. Professor Gama Pinto, 1649-003, Lisboa, Portugal.
- Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Sienkiewicza 112, 90-363, Lodz, Poland.
- Instituto de Biofísica e Engenharia Biomédica (IBEB), Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016, Lisboa, Portugal.
ORCID-Profile: Monika Marcinkowska, Kinga Piórecka, Catarina Pinto Reis, Jan Kurjata, Barbara Klajnert-Maculewicz
Förderung
- EU Regional Operational Program of the Lodz Region
Zitieren
APA
Marcinkowska, M., Antunes, M., Piórecka, K., Pinto Reis, C., Kurjata, J., Stańczyk, W., & Klajnert-Maculewicz, B. (2026). Cisplatin Derivatives and Their Complexes with PAMAM Dendrimers—A Way to Improve the Efficacy of Anticancer Drugs. ChemMedChem. https://doi.org/10.1002/cmdc.202500881
Vancouver
Marcinkowska M, Antunes M, Piórecka K, Pinto Reis C, Kurjata J, Stańczyk W, et al. Cisplatin Derivatives and Their Complexes with PAMAM Dendrimers—A Way to Improve the Efficacy of Anticancer Drugs. ChemMedChem. 2026. doi:10.1002/cmdc.202500881
BibTeX
@article{Marcinkowska2026,
author = {Marcinkowska, Monika and Antunes, Mariana and Piórecka, Kinga and Pinto Reis, Catarina and Kurjata, Jan and Stańczyk, Włodzimierz and Klajnert-Maculewicz, Barbara},
title = {Cisplatin Derivatives and Their Complexes with PAMAM Dendrimers—A Way to Improve the Efficacy of Anticancer Drugs},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.202500881}
}
EUVIMED